Skip to main content

Geographic Atrophy progression is constant and irreversible

Geographic Atrophy impairs functional vision with a substantial impact on patients’ independence and quality of life, and gradually leads to irreversible vision loss.1,2

Geographic Atrophy

Complement overactivation is associated with lesion growth in Geographic Atrophy3

Geographic Atrophy

Join us on our journey in
Geographic Atrophy

Geographic Atrophy

The impact of Geographic Atrophy

Geographic Atrophy is the advanced stage of dry age-related macular degeneration (AMD) and is characterised by progressive and irreversible loss of the photoreceptors, retinal pigment epithelium (RPE) and the underlying choriocapillaris.3

With currently no approved treatments available, it is the most significant unmet medical need in ophthalmology.4

Geographic Atrophy (GA) and advanced dry AMD

are both terms used to describe the advanced form of dry age-related macular degeneration (AMD), which is a leading cause of blindness worldwide.3,5

Over 5 million people worldwide are affected by Geographic Atrophy, with prevalence increasing with age.6 Geographic Atrophy has a significant and negative impact on vision and quality of life.7 - 5 million people are affected by Geographic Atrophy
Geographic Atrophy

Complement overactivation

has been detected systemically in age-related macular degeneration (AMD) and locally in patients with Geographic Atrophy.8

Are you looking for supportive patient materials? - dryAMD logo is a website dedicated to providing information and support
to those affected by advanced dry age-related macular degeneration (AMD) or Geographic Atrophy, as well as those who care for them.

The website has been created with patients living with blindness to ensure that it truly meets the needs of people with age-related macular degeneration. - Infographics icon

INFOGRAPHICS - videos icon

VIDEOS - podcast icon

PODCASTS - resources icon

RESOURCES - About Apellis

About Apellis

We are a global biopharmaceutical company leveraging courageous science, creativity and compassion to deliver life-changing medicines. As leaders in the research of targeted C3 therapies, we aim to develop new therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within haematology, nephrology, neurology and ophthalmology.

Join us on our journey in Geographic Atrophy

What do you get after registering for our newsletter?

Geographic Atrophy

Access presentations and recordings of past medical events

Geographic Atrophy

Receive news and updates about GA from Apellis


  1. Sivaprasad, S. et al. Living with Geographic Atrophy: An Ethnographic Study. Ophthalmology and Therapy8(1), 115–124.
  2. Patel, P. et al. (2020). Burden of Illness in Geographic Atrophy: A Study of Vision-Related Quality of Life and Health Care Resource Use. Clinical Ophthalmology (Auckland, N.Z.), [online] 14, pp.15–28. doi:10.2147/OPTH.S226425.
  3. Fleckenstein, M. et al. (2018). The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology125(3), 369–390.
  4. RIQUET, D. (n.d.). Parliamentary question | Geographic atrophy as an unmet medical need in the field of ophthalmology | P-000876/2022 | European Parliament. [online] Available at: Accessed July 20, 2022.
  5. Gehrs, K.M.(2006). Age-related macular degeneration—emerging pathogenetic and therapeutic concepts. Annals of medicine, [online] 38(7), pp.450–471. doi:10.1080/07853890600946724.
  6. Wong, W.L. et al. (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health, 2(2), pp.e106–e116. doi:10.1016/s2214-109x(13)70145-1.
  7. Patel, P.J. et al. (2020). Burden of Illness in Geographic Atrophy: A Study of Vision-Related Quality of Life and Health Care Resource Use. Clinical Ophthalmology (Auckland, N.Z.), [online] 14, pp.15–28. doi:10.2147/OPTH.S226425.
  8. Scholl, H.P. et al. (2008). Systemic complement activation in age-related macular degeneration. PloS One, [online] 3(7), p.e2593. doi:10.1371/journal.pone.0002593.


This site uses cookies to store information on your computer.

By clicking “Reject all” only strictly necessary cookies will be used Kindly be aware that when clicking “Accept all” cookies or choosing to enable performance/analytics cookies, your data will be transferred to the USA. You can always manage and change your cookie settings at any point of time by clicking on our Cookie Statement. Please note that blocking some types of cookies may impact your experience on the site and the services we are able to offer.